Medication Assisted Treatment (MAT): Are we replacing one addiction for another?

Activity Details
  • Credit Type: CPE
  • Credit Amount: 1.00
  • Cost: Free
  • Release: Feb 1, 2019
  • Expires: Oct 5, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (2 Ratings)
Didin't officially launch until November 20, 2019

Faculty

Hannah Johnson Hannah Johnson, PharmD, BCPS, BCPP
Assistant Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky

Needs Statement

Medications to treat opioid use disorder (OUD) are not widely used. Providers have misconceptions about medication use for OUD and education on current FDA-approved medications for OUD is needed.

Target Audience

Pharmacists

Objectives

Upon completion of this activity, participants will be able to:
1. Review the diagnosis and prevalence of OUD
2. Discuss FDA-approved medications to treat OUD
3. Identify common misconceptions associated with MAT

Accreditation

CPE
ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-18-176-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Faculty Disclosure

Hannah Johnson, PharmD (Speaker) her husband has relevant financial relationships with commercial interests as follows: Consultant - Slayback Pharmaceuticals.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.